Vera Therapeutics, Inc. (VERA)

Vera Therapeutics’ loss per share topped expectations even as the company posted a wider year-over-year net loss, based on preliminary results for the second fiscal quarter of 2026 reported August 10, 2026. EPS of -$1.52 topped the -$1.58 estimate by $0.06, and was down -26.7% from -$1.20 a year ago as the clinical-stage biotech continued investing in its lead programs, including atacicept and MAU868. Net income was a loss of roughly $109.5 million, down -43.0% from a loss of about $76.5 million a year ago, while operating income came in at a loss of about $112.5 million. Cash use remained elevated, with negative operating cash flow of roughly $100.3 million in the quarter. For the next period, consensus calls for EPS of -$1.61 on revenue of $4.3 million.